A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

NCT02068079 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Vemurafenib and Trientine

Sponsor

Duke University